Magnetic nanoparticles in theranostics of malignant melanoma.
Maxim ShevtsovSusanne KaeslerChristian PoschGabriele MulthoffTilo BiedermannPublished in: EJNMMI research (2021)
Malignant melanoma is an aggressive tumor with a tendency to metastasize early and with an increasing incidence worldwide. Although in early stage, melanoma is well treatable by excision, the chances of cure and thus the survival rate decrease dramatically after metastatic spread. Conventional treatment options for advanced disease include surgical resection of metastases, chemotherapy, radiation, targeted therapy and immunotherapy. Today, targeted kinase inhibitors and immune checkpoint blockers have for the most part replaced less effective chemotherapies. Magnetic nanoparticles as novel agents for theranostic purposes have great potential in the treatment of metastatic melanoma. In the present review, we provide a brief overview of treatment options for malignant melanoma with different magnetic nanocarriers for theranostics. We also discuss current efforts of designing magnetic particles for combined, multimodal therapies (e.g., chemotherapy, immunotherapy) for malignant melanoma.
Keyphrases
- magnetic nanoparticles
- early stage
- locally advanced
- cancer therapy
- molecularly imprinted
- squamous cell carcinoma
- drug delivery
- small cell lung cancer
- risk factors
- photodynamic therapy
- pain management
- angiotensin converting enzyme
- sentinel lymph node
- fluorescence imaging
- quality improvement
- neoadjuvant chemotherapy
- risk assessment
- free survival
- chronic pain
- mass spectrometry
- high resolution
- angiotensin ii
- liquid chromatography